Paroxysmal Atrial Fibrillation as the First Presentation of Coronary Artery Spasm

Atrial fibrillation (AF) represents a prevalent cardiac arrhythmia characterized by rising global incidence and significant associations with patient morbidity and mortality. Clinical guidelines identify coronary artery disease (CAD) as a major predisposing factor for the development of these irregular heart rhythms. Prior research has shown that myocardial ischemia resulting from obstructive vascular lesions frequently triggers electrical instability within the atria. While traditional atherosclerotic disease is well-documented, the role of non-obstructive functional abnormalities remains less clearly defined in routine clinical practice. Coronary vasospasm constitutes an uncommon manifestation of ischemic heart disease that only infrequently presents with supraventricular tachyarrhythmias. This specific form of CAD involves the sudden, temporary narrowing of the epicardial arteries, which can lead to transient myocardial ischemia even in the absence of fixed blockages. This absence of evidence motivated the documentation of rare clinical presentations where vasospastic events serve as the primary driver for paroxysmal rhythm disturbances.

This clinical report details the diagnostic journey of an adult male smoker presenting with recurrent palpitations initially managed as isolated paroxysmal atrial fibrillation (AF). The investigation seeks to clarify the relationship between episodic chest pain and the onset of tachyarrhythmia in patients without traditional cardiovascular risk factors. Clinicians evaluated the potential for coronary vasospasm to act as the underlying trigger for electrical remodeling and subsequent rhythm instability. The narrative emphasizes the importance of identifying functional coronary abnormalities when standard anatomical assessments appear unremarkable. By documenting the successful resolution of symptoms through targeted pharmacological intervention, the report advocates for a broader diagnostic perspective in arrhythmia management. The study highlights the necessity of integrating vasospasm screening into the holistic care of patients with unexplained paroxysmal AF. Researchers aimed to demonstrate that treating the underlying vascular spasm could effectively eliminate the secondary arrhythmic episodes.

Medical professionals conducted a comprehensive evaluation of a male patient experiencing recurrent palpitations and subsequent acute chest pain over a twelve-month period. Initial diagnostic steps included a thorough review of family history and lifestyle factors, identifying smoking as the sole significant risk contributor. The clinical team performed coronary angiography to visualize the vascular architecture and rule out obstructive atherosclerotic lesions that might explain the ischemic symptoms. Following the observation of normal coronary anatomy, the physicians administered a provocation test to assess the reactivity of the epicardial vessels under controlled conditions. This specific challenge successfully induced a vasospastic response while simultaneously triggering the patient's characteristic arrhythmia, providing a definitive diagnosis. Therapeutic management involved the administration of the calcium channel blocker (CCB) nifedipine alongside isosorbide mononitrate to maintain vascular patency and prevent future spasms. The medical team monitored the patient's response to this vasodilator therapy to ensure both the chest pain and the paroxysmal AF were adequately suppressed.

Coronary angiography revealed entirely normal coronary anatomy, effectively excluding significant obstructive coronary artery disease as the cause of the patient's symptoms. The subsequent provocation test confirmed the presence of coronary artery spasm, which directly coincided with the development of paroxysmal atrial fibrillation (AF). This finding established a clear temporal and mechanistic link between the vasospastic event and the onset of the cardiac arrhythmia in this patient. Pharmacological intervention using the calcium channel blocker nifedipine and the long-acting nitrate isosorbide mononitrate successfully prevented further episodes of chest pain. The patient remained free from recurrent paroxysms of AF following the initiation of this targeted vasodilator regimen, confirming the efficacy of the treatment strategy. These clinical outcomes demonstrate that resolving the underlying vasospasm effectively stabilizes the atrial rhythm in this specific patient population. The absence of further arrhythmic events during the follow-up period underscores the importance of addressing the primary vascular trigger rather than focusing solely on rhythm control.

Coronary artery spasm represents a primary diagnostic consideration for patients presenting with paroxysmal atrial fibrillation (AF), particularly when chest pain is a concurrent symptom. Holistic management of atrial arrhythmias must incorporate a thorough assessment of potential ischemic triggers, including functional vascular disorders like vasospasm. The successful use of calcium channel blockers (CCBs) in this case suggests that these agents serve a dual purpose in managing both vasospasm and secondary rhythm disturbances. Future clinical protocols should prioritize the identification of coronary vasoreactivity in patients who do not respond to standard antiarrhythmic therapies or who lack traditional CAD risk factors. Physicians should maintain a high index of suspicion for vasospastic disease even in the absence of traditional atherosclerotic risk factors, as smoking may be the only indicator. This approach ensures that the root cause of the arrhythmia is addressed, potentially reducing the long-term burden of paroxysmal AF and improving patient quality of life. The study concludes that coronary dilators should be considered a primary treatment modality when vasospasm is identified as the underlying cause of atrial fibrillation.